Find evidence gaps, conflicts, counter-evidence, and freshness signals before human review.
This existing Tynixa capability is integrated as a product workflow. It supports audit-ready, human-reviewed genomic review using synthetic or de-identified demo context.
Open review package demo is available as the safe package-context path for this capability.
Signals can be attached to a review-ready package for qualified human review.
Uncertainty, conflicts, and policy blocks route to reviewer or lab director workflows.
The demo shows evidence maturity, governance, and pilot readiness without unsafe claims.
Surface evidence gaps, counter-evidence, freshness issues, and evidence graph context before review.
Labs, reviewers, and researchers working with synthetic or de-identified review packages.
Links to counter-evidence, freshness, graph, and missing-evidence views with review package context.
No final diagnosis. Evidence intelligence does not finalize clinical meaning or override qualified human review.
A review package highlights five evidence gaps and one conflict signal before reviewer sign-off.
Run safe demo, open review package context, or inspect a specific evidence capability.
Evidence intelligence shows why a draft needs review by surfacing gaps, conflicts, freshness issues, and graph context.
Missing functional, segregation, population, transcript, or phenotype evidence is visible before review.
Basis: evidence gap cards
Evidence that may weaken a draft interpretation is highlighted for reviewers.
Basis: counter-evidence workflow
Evidence signals connect back to the review package rather than producing final clinical conclusions.
Basis: review package context
Safety: These value moments are event-based and review-context-only. They do not claim autonomous diagnosis, final ACMG classification, treatment decisions, clinical performance approval, regulatory approval, unsupervised clinical automation, same-visit final clinical decisions, or clinical release without qualified human sign-off.